Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Current Deferred Revenue (2016 - 2025)

STRATA Skin Sciences' Current Deferred Revenue history spans 14 years, with the latest figure at $2.2 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue changed 0.31% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a 0.31% change, with the full-year FY2025 number at $2.2 million, changed 0.31% from a year prior.
  • Current Deferred Revenue hit $2.2 million in Q4 2025 for STRATA Skin Sciences, down from $2.6 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for SSKN hit a ceiling of $3.8 million in Q3 2021 and a floor of $2.1 million in Q4 2023.
  • Historically, Current Deferred Revenue has averaged $2.6 million across 5 years, with a median of $2.4 million in 2023.
  • Biggest five-year swings in Current Deferred Revenue: soared 132.84% in 2021 and later fell 25.12% in 2023.
  • Tracing SSKN's Current Deferred Revenue over 5 years: stood at $3.3 million in 2021, then decreased by 15.43% to $2.8 million in 2022, then fell by 23.69% to $2.1 million in 2023, then increased by 5.71% to $2.2 million in 2024, then increased by 0.31% to $2.2 million in 2025.
  • Business Quant data shows Current Deferred Revenue for SSKN at $2.2 million in Q4 2025, $2.6 million in Q3 2025, and $2.4 million in Q2 2025.